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Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide (1). With advances in imaging diagnostics, together with the understanding of high-risk patients, the cancer can be often detected at an early stage now (2). Surgical treatments including hepatic resection and liver transplantation are considered as the most effective treatment for HCC. However, it is still not rare to find patients in whom HCC
Primary infection of HCC after TAE has been reported at an incidence of 0 to 5.3% (7, 8) , and occurs mostly on the basis of ischemic injury (9) . Hence, Castells et (11) . (13, 14) . In particular, previous studies have shown that hepatic abscesses are increasingly likely to form after TAE treatment in patients with a history of biliary reconstructive surgery (7, 15 
In this issue of Internal Medicine, Ebisutani et al document an open randomized prospective study of oral versus intravenous administration for antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma. They conclude that the results of peroral administration of LVFX for the prevention of post procedure infectious complications in patients receiving TACE/TAI for HCC are not inferior to those of intravenous administration of CEZ (12). Hence, administration of prophylactic antibiotics might decrease the overall prevalence of infectious complications of TAE, but it does not decrease the prevalence of liver abscess (6). However, some authors report hepatic abscess formation as a potential complication of TAE. TAE causes ischemia and increases the risk of infection. Hepatic infarcts act as a nidus for bacterial colonization by organisms that enter through the portal vein

